Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.

Cardiol Clin · 2025

Last updated 2026-05-28

GLP-1 drugs, originally used to lower blood sugar in people with type 2 diabetes, are now also recognized for helping with weight management and reducing risks of heart and kidney problems. Large studies show these drugs improve blood sugar control and support weight goals, and early evidence suggests similar benefits from a newer drug called tirzepatide, which targets both GLP-1 and GIP.

AI summary of the abstract below.

Journal	Cardiol Clin, 2025
Citations	1
Molecules	—
Conditions studied	Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction, Chronic Kidney Disease, Mash

Abstract

Use of glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, initially developed as glucose-lowering therapies for the management of type 2 diabetes, continues to expand in parallel with our understanding of their beneficial effects on cardiovascular-kidney-metabolic conditions. Large clinical outcome trials have established GLP-1 receptor agonists as guideline-directed therapies to improve glycemia, achieve, and maintain weight management goals, and mitigate cardiovascular and kidney risk, with early evidence suggesting similar benefits with the dual GIP/GLP-1 receptor agonist tirzepatide.

Verbatim abstract via PubMed 40582734 ↗